Search details
1.
Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study).
BMC Cancer
; 24(1): 91, 2024 Jan 17.
Article
in English
| MEDLINE | ID: mdl-38233810
2.
Efficacy and toxicity of primary re-irradiation for malignant spinal cord compression based on radiobiological modelling: a phase II clinical trial.
Br J Cancer
; 128(4): 576-585, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36482188
3.
Non-inferiority randomised phase 3 trial comparing two radiation schedules (single vs. five fractions) in malignant spinal cord compression.
Br J Cancer
; 122(9): 1315-1323, 2020 04.
Article
in English
| MEDLINE | ID: mdl-32157242
4.
Modifiable Risk Factors and Risk of Colorectal and Endometrial Cancers in Lynch Syndrome: A Systematic Review and Meta-Analysis.
JCO Precis Oncol
; 8: e2300196, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38207227
5.
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial.
Lancet Gastroenterol Hepatol
; 8(11): 1015-1027, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37734399
6.
HPV vaccination among seropositive, DNA negative cohorts: a systematic review & meta-analysis.
J Gynecol Oncol
; 33(3): e24, 2022 05.
Article
in English
| MEDLINE | ID: mdl-35128855
7.
Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study.
Ther Adv Med Oncol
; 13: 17588359211042691, 2021.
Article
in English
| MEDLINE | ID: mdl-34512801
8.
Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER".
Cancers (Basel)
; 13(6)2021 Mar 11.
Article
in English
| MEDLINE | ID: mdl-33799597
9.
Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial.
Ther Adv Med Oncol
; 11: 1758835919864236, 2019.
Article
in English
| MEDLINE | ID: mdl-31384312
10.
Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.
Leuk Lymphoma
; 59(6): 1338-1347, 2018 06.
Article
in English
| MEDLINE | ID: mdl-28925785
Results
1 -
10
de 10
1
Next >
>>